Please login to the form below

Not currently logged in
Email:
Password:

Peter Chambre joins cancer vaccine biotech Immatics

He replaces Thomas Widmann as chair of the board

Immatics Peter ChambreImmatics Biotechnologies has appointed Peter Chambré as chairman of the board to replace Thomas Widmann, who steps down after eight years in the post.

Chambré holds several chairman positions in the life sciences industry and previously served as CEO of Cambridge Antibody Technology from 2002 until its acquisition by AstraZeneca in 2006.

Paul Higham, CEO of Immatics, said: “I am delighted to welcome Peter as our new chairman. We are approaching a crucial period at Immatics, and Peter's experience and track record in successfully developing biopharmaceutical companies will be invaluable, as we seek to produce a step-change in the treatment of cancer and maximise returns to our investors.”

Chambré joins Tuebingen-based Immatics following the German biotech's recent completion of phase III patient enrollment for a trial of its therapeutic vaccine for renal cancer IMA901.

He said: “Immatics' vaccines, based on the company's highly rational approach to cancer vaccine discovery, have already demonstrated very promising results in clinical trials.

“With IMA901, Immatics' lead multi-peptide based vaccine now in phase III development for renal cancer, and a number of other projects in clinical development, this is an extremely exciting company.”

14th November 2012

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics